Zeotec Life Science Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 0.70 M
- Revenue Growth 36.53%
- Profit Growth 54.81%
- Ebitda -14.70%
- Net Worth 13.62%
- Total Assets -4.88%
About Zeotec Life Science
Zeotec Life Science Private Limited (ZLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 September 2013 and has a history of 11 years and four months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.70 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Narendra Jha and Swati Jha serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24233GJ2013PTC076778
- Company No.
076778
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Zeotec Life Science?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swati Jha  | Director | 25-Dec-2019 | Current |
| Narendra Jha | Director | 11-Sep-2013 | Current |
Financial Performance of Zeotec Life Science.
Zeotec Life Science Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 36.53% increase. The company also saw a substantial improvement in profitability, with a 54.81% increase in profit. The company's net worth Soared by an impressive increase of 13.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeotec Life Science?
In 2021, Zeotec Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹0.70 M
Charges Breakdown by Lending Institutions
- Dena Bank : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 2014 | Dena Bank | ₹0.70 M | Satisfied |
How Many Employees Work at Zeotec Life Science?
Unlock and access historical data on people associated with Zeotec Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeotec Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeotec Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
